文献速递血液净化与透析肾血管病与高血压

阿哌沙班给药模式与华法林在接受透析的非瓣膜性心房颤动患者中的比较:回顾性队列研究

Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2022-04-22

该回顾性队列研究基于美国肾脏数据系统2013-2018年数据,纳入17,156例接受维持性透析的非瓣膜性心房颤动患者,比较按标签剂量阿哌沙班、低于标签剂量阿哌沙班与华法林的临床结局。结果显示,两种阿哌沙班给药方式的主要出血风险均低于华法林,按标签剂量阿哌沙班的全因死亡风险也低于华法林,而低于标签剂量与按标签剂量阿哌沙班的主要出血风险无显著差异。作者认为按标签剂量阿哌沙班可能提供最佳获益-风险平衡。

要点

  • 在透析合并非瓣膜性房颤患者中,按标签剂量和低于标签剂量阿哌沙班的主要出血风险均低于华法林。
  • 按标签剂量阿哌沙班的全因死亡风险低于华法林,低于标签剂量阿哌沙班与华法林无显著差异。
  • 低于标签剂量阿哌沙班的主要出血风险与按标签剂量相比无显著差异。

核心结论

  • 在接受透析的非瓣膜性房颤患者中,华法林的主要出血风险高于阿哌沙班。
  • 低于标签剂量阿哌沙班的主要出血风险未检测到低于按标签剂量。
  • 按标签剂量阿哌沙班较华法林与死亡获益相关。
  • 按标签剂量而非减量给药可能为透析合并非瓣膜性房颤患者提供最有利的获益-风险平衡。

研究设计与样本

  • 回顾性队列研究,使用2013-2018年美国肾脏数据系统数据库。
  • 纳入17,156例接受维持性透析、合并非瓣膜性心房颤动并接受阿哌沙班或华法林治疗的患者。
  • 暴露为首次处方按标签剂量阿哌沙班、低于标签剂量阿哌沙班或华法林。
  • 采用Cox比例风险模型及逆概率治疗加权,并模拟意向性治疗分析及药物转换或停药时删失分析。

主要发现

  • 按标签剂量阿哌沙班、低于标签剂量阿哌沙班与华法林三组间的卒中/系统性栓塞风险无差异。
  • 意向性治疗分析中,按标签剂量阿哌沙班的主要出血风险低于华法林(HR 0.67,95%CI 0.55-0.81)。
  • 意向性治疗分析中,低于标签剂量阿哌沙班的主要出血风险低于华法林(HR 0.68,95%CI 0.55-0.84)。
  • 低于标签剂量阿哌沙班与按标签剂量相比,主要出血风险无显著差异(HR 1.02,95%CI 0.78-1.34)。
  • 意向性治疗分析中,按标签剂量阿哌沙班的全因死亡风险低于华法林(HR 0.85,95%CI 0.78-0.92),低于标签剂量阿哌沙班与华法林无显著差异(HR 0.97,95%CI 0.89-1.05)。

临床怎么用

  • 原文结论指出,按标签剂量阿哌沙班而非减量给药可能为透析合并非瓣膜性房颤患者提供最有利的获益-风险平衡。

局限性

  • 研究仅限于美国Medicare受益人。
  • 依赖行政索赔数据确定心房颤动、卒中和出血结局。
  • 可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & OBJECTIVES: Comparison of clinical outcomes across anticoagulation regimens using different apixaban dosing or warfarin is not well-defined in patients with nonvalvular atrial fibrillation (AF) who are receiving dialysis. This study compared these outcomes in a US national cohort of patients with kidney failure receiving maintenance dialysis. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Patients receiving dialysis represented in the US Renal Data System database 2013-2018 who had AF and were treated with apixaban or warfarin. EXPOSURE: First prescribed treatment with apixaban dosed according to the label, apixaban dosed below the label, or warfarin. OUTCOME: Ischemic stroke/systemic embolism, major bleeding, and all-cause mortality. ANALYTICAL APPROACH: Cox proportional hazards models with inverse probability of treatment weighting. Analyses simulating an intention-to-treat (ITT) approach as well as those incorporating censoring at drug switch or discontinuation (CAS) were also implemented. Inverse probability of censoring weighting was used to account for possible informative censoring. RESULTS: Among 17,156 individuals, there was no difference in risk of stroke/systemic embolism among the label-concordant apixaban, below-label apixaban, and warfarin treatment groups. Both label-concordant (HR, 0.67 [95% CI, 0.55-0.81]) and below-label (HR, 0.68 [95% CI, 0.55-0.84]) apixaban dosing were associated with a lower risk of major bleeding compared with warfarin in ITT analyses. Compared with label-concordant apixaban, below-label apixaban was not associated with a lower bleeding risk (HR, 1.02 [95% CI, 0.78-1.34]). In the ITT analysis of mortality, label-concordant apixaban dosing was associated with a lower risk versus warfarin (HR, 0.85 [95% CI, 0.78-0.92]) while there was no significant difference in mortality between below-label dosing of apixaban and warfarin (HR, 0.97 [95% CI, 0.89-1.05]). Overall, results were similar for the CAS analyses. LIMITATIONS: Study limited to US Medicare beneficiaries; reliance on administrative claims to ascertain outcomes of AF, stroke, and bleeding; likely residual confounding. CONCLUSIONS: Among patients with nonvalvular AF undergoing dialysis, warfarin is associated with an increased risk of bleeding compared with apixaban. The risk of bleeding with below-label apixaban was not detectably less than with label-concordant dosing. Label-concordant apixaban dosing is associated with a mortality benefit compared to warfarin. Label-concordant dosing, rather than reduced-label dosing, may offer the most favorable benefit-risk trade-off for dialysis patients with nonvalvular AF.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Wetmore JB, Weinhandl ED, Yan H, et al. Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study. Am J Kidney Dis. 2022. PMID: 35469965. doi:10.1053/j.ajkd.2022.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。